In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $107.95 in the prior trading day, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $105.35, down -2.41%. In other words, the price has decreased by -$2.41 from its previous closing price. On the day, 1.31 million shares were traded.
Ratios:
Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.03 and its Current Ratio is at 3.84. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Hold rating and assigned the stock a target price of $136.
On November 27, 2024, Needham reiterated its Buy rating and also upped its target price recommendation from $205 to $202.
On November 25, 2024, H.C. Wainwright started tracking the stock assigning a Sell rating and target price of $80.H.C. Wainwright initiated its Sell rating on November 25, 2024, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 12 ’24 when Wigzell Hans Lennart Rudolf sold 10,500 shares for $124.84 per share. The transaction valued at 1,310,820 led to the insider holds 22,840 shares of the business.
Wigzell Hans Lennart Rudolf bought 10,500 shares of SRPT for $1,310,400 on Dec 12 ’24. On Dec 05 ’24, another insider, Boor Kathryn Jean, who serves as the Director of the company, sold 1,636 shares for $125.55 each. As a result, the insider received 205,400 and left with 5,880 shares of the company.
Valuation Measures:
As of this moment, Sarepta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 87.51, and their Forward P/E ratio for the next fiscal year is 8.83. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.13 while its Price-to-Book (P/B) ratio in mrq is 8.24.
Stock Price History:
Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $102.15. The 50-Day Moving Average of the stock is -11.76%, while the 200-Day Moving Average is calculated to be -17.97%.
Shares Statistics:
A total of 95.49M shares are outstanding, with a floating share count of 89.14M. Insiders hold about 6.67% of the company’s shares, while institutions hold 92.64% stake in the company.
Earnings Estimates
The current rating of Sarepta Therapeutics Inc (SRPT) is the result of assessments by 11.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $1.95, with high estimates of $3.24 and low estimates of -$0.81.
Analysts are recommending an EPS of between $4.91 and $3.41 for the fiscal current year, implying an average EPS of $4.02. EPS for the following year is $11.65, with 12.0 analysts recommending between $14.5 and $5.49.
Revenue Estimates
17 analysts predict $631.03M in revenue for the current quarter. It ranges from a high estimate of $671.2M to a low estimate of $575.3M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $396.78MFor the next quarter, 17 analysts are estimating revenue of $698.26M. There is a high estimate of $751.88M for the next quarter, whereas the lowest estimate is $640.3M.
A total of 19 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $1.91B, while the lowest revenue estimate was $1.34B, resulting in an average revenue estimate of $1.84B. In the same quarter a year ago, actual revenue was $1.24BBased on 19 analysts’ estimates, the company’s revenue will be $3.16B in the next fiscal year. The high estimate is $3.46B and the low estimate is $2.92B.
